Novel Drug for Relapsing-Remitting MS: New Phase 2 Data ...Middle East

Medscape - News
The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated. Medscape Medical News

Hence then, the article about novel drug for relapsing remitting ms new phase 2 data was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Drug for Relapsing-Remitting MS: New Phase 2 Data )

Apple Storegoogle play

Last updated :

Also on site :



Latest News